Enovis Corporation (ENOV)
Valuation Overview•Is Enovis Corporation Overvalued or Undervalued?
Trading at a discount across both intrinsic cash flow and relative peer multiples, indicating a strong margin of safety.
Fragile underlying quality score of 37/100; weak margins or elevated debt leverage warrant caution.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: Mixed fundamental profile with offsetting strengths and weaknesses.
Wall Street is highly bullish, projecting significant upside alongside robust expected earnings growth. The company currently dilutes shareholders to fund operations and growth rather than returning capital.
ENOV struggles with subpar profitability and pressured margins. However, the balance sheet carries elevated leverage, requiring careful monitoring of debt servicing capabilities.
The company demonstrates solid revenue growth (12.9% 3Y CAGR) paired with stable bottom-line earnings. However, profitability remains a major concern with severely compressed operating margins (2.7%).
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $589.2M | +6.7% | +12.9% | +14.9% | -5.5% | |
| EBITDA | $93.6M | — | +22.9% | — | — | |
| Net Income | -$8.8M | -43.5% | -346.7% | — | — | |
| EPS (Diluted) | $-0.15 | -39.7% | — | — | — | |
| Free Cash Flow | -$28.9M | +129.6% | — | -36.1% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 56.8% | 58.0% | 56.8% | 47.4% |
| Operating Margin | 2.7% | -13.8% | -10.1% | -3.6% |
| Net Margin | -49.9% | -31.3% | -17.9% | -9.0% |
| FCF Margin | 1.6% | -0.5% | 1.2% | 3.7% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $0.82 | $0.89 | +8.5% | ||
| Q1'26 | $0.81 | $0.95 | +17.3% | ||
| Q4'25 | $0.67 | $0.75 | +11.9% | ||
| Q3'25 | $0.74 | $0.79 | +6.8% | ||
| Q2'25 | $0.74 | $0.81 | +9.5% | ||
| Q1'25 | $0.92 | $0.98 | +6.5% | ||
| Q4'24 | $0.63 | $0.73 | +15.9% | ||
| Q3'24 | $0.60 | $0.62 | +3.3% |
Total return is -28.3% (1Y), lagging the benchmark by -53.3%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -17.1% | -26.4% | — |
| 1Y | -28.3% | -53.3% | — |
| 3YCAGR | -28.4% | -49.2% | — |
| 5YCAGR | -21.8% | -35.5% | — |
| 10YCAGR | -8.1% | -21.8% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Enovis Corporation (ENOV) valuation, health, and returns.
Enovis Corporation is estimated to be undervalued under our discounted cash flow framework. relative multiples indicate the stock is Cheap versus peers compared to industry peers. undervalued (implying +215.8% upside to DCF intrinsic value of $69.39)
Enovis Corporation has multiple valuation anchors: DCF Intrinsic Value: $69.39 | Peer Relative Fair Value: $71.18 | Wall Street Analyst Target: $44.75 (implying +103.7% upside). A convergence of these signals offers higher conviction.
Enovis Corporation displays weak financial health with a composite quality score of 37/100, supported by a Altman Z-Score of 0.0 (distress zone), Piotroski F-Score of 4/9, Return on Invested Capital (ROIC) of -0.4%.
Enovis Corporation does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Enovis Corporation's current growth trajectory is Decelerating. The company achieved +6.7% 1Y revenue growth and -39.7% 1Y EPS growth, compared to its 3Y revenue CAGR of +12.9%.
Wall Street consensus is Buy based on 13 analysts, beating EPS expectations in 92% of recent quarters with a 8-quarter streak. The consensus price target represents a +103.7% change from current levels.
Investment risks for Enovis Corporation include: -42.0% 1-year max drawdown, high beta (1.65x market volatility), elevated distress risk. Volatility risk is characterized by a beta of 1.65x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.